Structure of Imatinib Mesylate
CAS No.: 220127-57-1
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinase inhibitor that targets c-Kit, Bcr-Abl, and PDGFR, with an IC50 of 100 nM.
Synonyms: STI571 Mesylate; CGP-57148B Mesylate; STI-571
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Jiang, Qi ; Ghosh, Rittik K ; Valdivia-Berroeta, Gabriel A ; Walder, Brennan J ; Luo, Laibin ;
Abstract: We focused on the critical role of crystallization of active pharmaceutical ingredients (APIs) in drug development, with particular emphasis on stability, solubility, and the feasibility of drug formulation and manufacturing. We explored polymorphism in APIs and the formation of multicomponent crystals, including salt and cocrystal screening, underscoring the significance of regulatory and intellectual property considerations in recognizing salts and cocrystals of solid forms. Our study led to the design of seven new multicomponent crystalline forms of imatinib, an oncology API. Using X-ray crystallography and solid-state NMR, we elucidated hydrogen bonding interactions and proton transfer, unveiling multicomponent interactions in the crystalline solid forms along the salt−cocrystal continuum. Most of the new solid forms demonstrated improved aqueous solubility compared to that of the free base form. This research provides valuable insights into the structural details of solid forms of pharmaceutical compounds and emphasizes the importance of understanding solid-state interactions for the rational design of crystalline APIs, thereby enhancing the drug development process.
Show More >
| CAS No. : | 220127-57-1 |
| Formula : | C30H35N7O4S |
| M.W : | 589.71 |
| SMILES Code : | O=C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C4=CC=C(CN5CCN(C)CC5)C=C4.CS(=O)(O)=O |
| Synonyms : |
STI571 Mesylate; CGP-57148B Mesylate; STI-571
|
| MDL No. : | MFCD04307699 |
| InChI Key : | YLMAHDNUQAMNNX-UHFFFAOYSA-N |
| Pubchem ID : | 123596 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302-H315-H319-H332-H335 |
| Precautionary Statements: | P261-P280-P305+P351+P338 |
| Target |
|
In Vitro:
| Concentration | Treated Time | Description | References |
| GIST48 | 0.5, 1 µM | 72 h | Evaluate the effect of imatinib on apoptosis in GIST48 cells, results showed that imatinib treatment led to 39.5% apoptosis. | Br J Cancer. 2020 Feb;122(3):372-381. |
| GIST430/654 | 0.5, 1 µM | 72 h | Evaluate the effect of imatinib on apoptosis in GIST430/654 cells, results showed that imatinib treatment led to 31% apoptosis. | Br J Cancer. 2020 Feb;122(3):372-381. |
| GIST882 | 0.05, 0.5 µM | 72 h | Evaluate the effect of imatinib on apoptosis in GIST882 cells, results showed that imatinib treatment led to 14.9% apoptosis. | Br J Cancer. 2020 Feb;122(3):372-381. |
| GIST-T1 | 0.05, 0.5 µM | 72 h | Evaluate the effect of imatinib on apoptosis in GIST-T1 cells, results showed that imatinib treatment led to 14.3% apoptosis. | Br J Cancer. 2020 Feb;122(3):372-381. |
| LAMAs cells | 200 nM | 24 and 48 h | To investigate the effect of imatinib in combination with GSI on LAMAs cells, results showed that the combination treatment significantly reduced NOTCH1 signaling. | J Pathol. 2013 Nov;231(3):378-87. |
| KCL22s cells | 200 nM | 24 and 48 h | To investigate the effect of imatinib in combination with GSI on KCL22s cells, results showed that the combination treatment significantly reduced NOTCH1 signaling. | J Pathol. 2013 Nov;231(3):378-87. |
| K562 cells | 200 nM | 24 and 48 h | To investigate the effect of imatinib in combination with GSI on K562 cells, results showed that the combination treatment significantly reduced NOTCH1 signaling. | J Pathol. 2013 Nov;231(3):378-87. |
| KBM5-T315I cells | 1 μM | 24 h | To evaluate the inhibitory effect of imatinib on Bcr-Abl kinase activity in KBM5-T315I cells, results showed that imatinib had a weaker inhibitory effect on Bcr-Abl kinase activity with T315I mutation | Cell Discov. 2019 Apr 30;5:24. |
| KBM5 cells | 1 μM | 24 h | To evaluate the inhibitory effect of imatinib on Bcr-Abl kinase activity in KBM5 cells, results showed that imatinib significantly reduced the phosphorylation level of Bcr-Abl and SKP2 protein level | Cell Discov. 2019 Apr 30;5:24. |
| K562 cells | 3 μM | 6 h | Evaluate the inhibitory effect of imatinib on K562 cells, showing that erythropoietin can confer resistance to imatinib. | Nat Med. 2017 Apr;23(4):472-482. |
| BaF3-BA cells | 3 μM | 60 h | Evaluate the inhibitory effect of imatinib on BCR-ABL-expressing cells, showing that IL-3 can confer resistance to imatinib. | Nat Med. 2017 Apr;23(4):472-482. |
| BaF3-LTBA cells | 3 μM | 60 h | Evaluate the inhibitory effect of imatinib on BCR-ABL-expressing cells, showing that IL-3 can confer resistance to imatinib. | Nat Med. 2017 Apr;23(4):472-482. |
| abl pre-B cells | 3 μM | 2 days | To arrest abl pre-B cells in G0/G1 phase for studying DNA double-strand break repair mechanisms | Elife. 2021 Sep 3;10:e68466. |
| human microvascular endothelial cell line HMEC-1 | 0.01-20 µM | 48 h | To evaluate the effects of Imatinib on endothelial cell growth and function. Results showed that Imatinib had no significant effects on endothelial cell proliferation, migration, or tube formation. | Leukemia. 2017 Nov;31(11):2388-2397. |
| human coronary arterial endothelial cells (HCAEC) | 0.01-20 µM | 48 h | To evaluate the effects of Imatinib on endothelial cell growth and function. Results showed that Imatinib had no significant effects on endothelial cell proliferation, migration, or tube formation. | Leukemia. 2017 Nov;31(11):2388-2397. |
| human umbilical vein endothelial cells (HUVEC) | 0.01-20 µM | 48 h | To evaluate the effects of Imatinib on endothelial cell growth and function. Results showed that Imatinib had no significant effects on endothelial cell proliferation, migration, or tube formation. | Leukemia. 2017 Nov;31(11):2388-2397. |
| Mouse bone marrow cells | 0-10 μM | 48 h | To investigate the effects of imatinib and GW2580 on the differentiation of monocytes into macrophages. Results showed that GW2580 significantly inhibited macrophage formation at lower concentrations. | Arthritis Res Ther. 2010;12(1):R32. |
| Human peripheral blood mononuclear cells | 0-10 μM | 48 h | To assess the inhibitory effects of imatinib and GW2580 on c-Fms activity. Results showed that GW2580 significantly inhibited c-Fms activity at lower concentrations. | Arthritis Res Ther. 2010;12(1):R32. |
| Vero E6 cells | 25 μM | 6 h | To evaluate the effect of imatinib on SARS-CoV-2 infection, results showed that imatinib dramatically reduced the viral RNA in the cell culture medium by up to 89.1%–99.9%. | Cell Metab. 2022 Mar 1;34(3):424-440.e7. |
| Human umbilical vein endothelial cells (HUVECs) | 25 μM | 16 h | To evaluate the effect of imatinib on ACE2 enzymatic activity, results showed that imatinib significantly elevated the enzymatic activity of ACE2. | Cell Metab. 2022 Mar 1;34(3):424-440.e7. |
In Vivo:
| Administration | Dosage | Frequency | Description | References |
| Mice | Apoe−/− mice | Intraperitoneal injection | 100mg/kg/day | Once daily for 7 days | To test the effect of Imatinib on atherosclerotic plaque stability, results showed that Imatinib treatment led to a significant reduction in SMC-derived ACTA2+ cells in the fibrous cap and decreased plaque stability. | Nat Metab. 2021 Feb;3(2):166-181 |
| Mice | A431, LLC, and T241 tumor models | Oral | 50 mg/kg | Once daily until primary tumor removal | Imatinib significantly inhibited TAM recruitment in A431, LLC, and T241 tumors | Nat Commun. 2016 May 6;7:11385 |
| Mouse | Pten/Braf/Bcat-STA melanoma model | Oral gavage | 200 mg/kg | Daily administration | Inhibition of Kit receptor signaling significantly slowed growth of the primary tumor, but did not alter the frequency of metastasis. | Cancer Cell. 2011 Dec 13;20(6):741-54 |
| Mice | AT-GFP mice | Intraperitoneal injection | 50 mg/mouse | Four times a week for 4 weeks | To evaluate the effect of Imatinib on adipose tissue vascular niche, results showed that imatinib treatment improved glucose sensitivity but blunted subcutaneous and visceral fat expansion and altered APC niche interaction. | Nat Commun. 2017 Jun 26;8:15926 |
| Mice | BCR-ABL-induced chronic myeloid leukemia model | Intraperitoneal injection | 75 mg/kg | Twice daily for 3 months | Evaluate the therapeutic effect of imatinib alone or in combination with DFC and BCI on leukemic mice, showing that combination therapy can eradicate leukemic cells. | Nat Med. 2017 Apr;23(4):472-482. |
| ApoE-/- mice | Atherosclerosis model | Orally | 50 mg/kg | Twice daily for 8 weeks | To evaluate the effects of Imatinib on atherosclerosis. Results showed that Imatinib did not significantly promote atherosclerosis. | Leukemia. 2017 Nov;31(11):2388-2397. |
| DBA/1 mice | Collagen-induced arthritis (CIA) | Oral | 80 mg/kg | Twice daily, for the duration of the experiment | To evaluate the therapeutic efficacy of imatinib in CIA. Results showed that imatinib significantly reduced arthritis severity and histopathologic scores. | Arthritis Res Ther. 2010;12(1):R32. |
| Balb/c mice | Chronic myeloid leukemia model | Oral gavage | 50 mg/kg/day | Once daily for 2 weeks | To evaluate the therapeutic effect of imatinib on the chronic myeloid leukemia model. Results showed that imatinib prolonged the survival of Ba-F3p210 cell-transplanted mice but had no effect on Ba-F3T315I cell-transplanted mice. | Cancer Sci. 2023 Jan;114(1):247-258 |
| Mice | High-fat-diet-induced insulin-resistant mice | Gavage | 250 mg/kg | Once daily for 4 weeks | To evaluate the effect of imatinib on metabolic disorders in SARS-CoV-2-infected mice, results showed that imatinib significantly improved insulin resistance and dyslipidemia. | Cell Metab. 2022 Mar 1;34(3):424-440.e7. |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT01297777 | Systemic Mastocytosis | PHASE4 | COMPLETED | 2025-08-15 | Instituto de Estudios de Masto... More >>citosis de Castilla La Mancha; Hospital Virgen del Valle, Toledo, 45071, Spain Less << |
| NCT01221376 | Chronic Myeloid Leukemia (CML)... More >> With Philadelphia Chromosome-positive (Ph+) Less << | PHASE2 | UNKNOWN | 2025-12-13 | Hospital Santa Marcelina, Sao ... More >>Paulo, SP, 08270-070, Brazil Less << |
| NCT00237172 | Gastrointestinal Stromal Tumor... More >>s Less << | PHASE2 | COMPLETED | - | - |
| NCT00171977 | Gastrointestinal Stromal Tumor... More >>s Less << | PHASE4 | COMPLETED | - | Novartis Investigative Site, T... More >>okyo, Japan Less << |
| NCT00430066 | Polycythemia Vera | PHASE2 | COMPLETED | 2025-09-12 | - |
| NCT00510653 | Ovarian Cancer | PHASE2 | COMPLETED | 2025-02-12 | UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less << |
| NCT00555581 | Systemic Sclerosis | PHASE2 | COMPLETED | 2025-12-11 | Hospital for Special Surgery, ... More >>New York, New York, 10021, United States Less << |
| NCT05385549 | Gastrointestinal Stromal Tumor... More >>s Less << | PHASE2 | RECRUITING | 2030-04-30 | Asan Medical Center, Universit... More >>y of Ulsan College of Medicine, Seoul, 138-736, Korea, Republic of Less << |
| NCT04416750 | Pulmonary Arterial Hypertensio... More >>n Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2024-07-01 | Hammersmith Hospital, Imperial... More >> College Healthcare NHS Trust, London, Greater London, W12 0HS, United Kingdom|Royal Papworth Hospital, Royal Papworth Hospital NHS Foundation Trust, Cambridge, CB2 0AY, United Kingdom|Royal Brompton Hospital, Royal Brompton & Harefield NHS Foundation Trust, London, SW3 6NP, United Kingdom|Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation, Sheffield, S10 2JF, United Kingdom Less << |
| NCT03997903 | Sickle Cell Disease | PHASE1|PHASE2 | RECRUITING | 2025-09-25 | Riley Hospital for Children at... More >> IU Health, Indianapolis, Indiana, 46202, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, 45229, United States Less << |
| NCT00928525 | Advanced Desmoid Tumor|Advance... More >>d Chondrosarcoma Less << | PHASE2 | COMPLETED | 2025-12-18 | Centro di Riferimento Oncologi... More >>co - Unit of Medical Oncology, Aviano, Pordenone, 33081, Italy|I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, 10060, Italy|Istituti Ortopedici Rizzoli - Unit of chemotherapy of Muscoloskeletal Tumors, Bologna, 40136, Italy|Policlinico S.Orsola Malpighi - Unit of Medical Oncology, Bologna, 40138, Italy|Istituto Nazionale Tumori - Unit of Medical Oncology, Milano, 20133, Italy|Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I, Roma, 00144, Italy|Ospedale Gradenigo - Unit of Medical Oncology, Torino, 10153, Italy Less << |
| NCT02712112 | Gastrointestinal Stromal Tumor... More >>s (GISTs) Less << | PHASE2 | COMPLETED | 2019-06-15 | Asan Medical Center, Seoul, 13... More >>8-736, Korea, Republic of Less << |
| NCT01222013 | Acute Lymphoblastic Leukemia (... More >>ALL) Philadelphia Chromosome-positive (Ph+) Less << | PHASE2 | SUSPENDED | - | - |
| NCT00386373 | Leukemia | COMPLETED | 2025-10-07 | U.T.M.D. Anderson Cancer Cente... More >>r, Houston, Texas, 77030, United States Less << | |
| NCT00009906 | Gastrointestinal Stromal Tumor | PHASE3 | TERMINATED | 2025-11-14 | Western Regional CCOP, Phoenix... More >>, Arizona, 85006, United States|University of Arizona Health Sciences Center, Tucson, Arizona, 85724, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|Highlands Oncology Group-Rogers, Rogers, Arkansas, 72758, United States|City of Hope Comprehensive Cancer Center, Duarte, California, 91010, United States|Long Beach Community Hospital, Long Beach, California, 90804, United States|University of Southern California/Norris Cancer Center, Los Angeles, California, 90033, United States|University of California at Los Angeles Health System, Los Angeles, California, 90095, United States|Sutter Cancer Research Consortium, Novato, California, 94945, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|Kaiser Permanente - Sacramento, Sacramento, California, 95825, United States|University of California San Diego, San Diego, California, 92103, United States|UCSF Medical Center-Mount Zion, San Francisco, California, 94115, United States|Santa Rosa Memorial Hospital, Sana Rosa, California, 95405, United States|Stanford University Hospitals and Clinics, Stanford, California, 94305, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, 80218, United States|Rose Medical Center, Denver, Colorado, 80220, United States|Swedish Medical Center, Englewood, Colorado, 80113, United States|Poudre Valley Hospital, Fort Collins, Colorado, 80524, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, 81004, United States|Middlesex Hospital, Middletown, Connecticut, 06457, United States|MedStar Oncology Network, Washington, District of Columbia, 20010, United States|Mayo Clinic in Florida, Jacksonville, Florida, 32224-9980, United States|Hematology Oncology Associates, Lake Worth, Florida, 33461, United States|Florida Hospital Orlando, Orlando, Florida, 32803, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, 31701, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Atlanta Regional CCOP, Atlanta, Georgia, 30342, United States|Medical Center of Central Georgia, Macon, Georgia, 31208, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, 96813, United States|Hematology and Oncology Associates, Chicago, Illinois, 60611, United States|Northwestern University, Chicago, Illinois, 60611, United States|Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, 60612, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Illinois, Chicago, Illinois, 60612, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|Central Illinois CCOP, Decatur, Illinois, 62526, United States|Alexian Brothers Medical and Cancer Center, Elk Grove Village, Illinois, 60007, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, 60201, United States|Loyola University Medical Center, Maywood, Illinois, 60153, United States|Mid-Illinois Hematology Oncology Associates, Normal, Illinois, 61761, United States|Advocate Lutheran General Hospital., Park Ridge, Illinois, 60068, United States|Carle Cancer Center, Urbana, Illinois, 61801, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|IU Health Methodist Hospital, Indianapolis, Indiana, 46202, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, 50010, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Kansas City CCOP, Prairie Village, Kansas, 66208, United States|Stormont-Vail Regional Health Center, Topeka, Kansas, 66604, United States|Our Lady Bellefonte Hospital, Ashland, Kentucky, 41101, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, 70112, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, 21215, United States|Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Michigan Cancer Research Consortium Community Clinical Oncology Program, Ann Arbor, Michigan, 48106, United States|University of Michigan University Hospital, Ann Arbor, Michigan, 48109, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, 48124, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, 49503, United States|West Michigan Cancer Center, Kalamazoo, Michigan, 49007, United States|Marquette General Hospital, Marquette, Michigan, 49855, United States|Unity Hospital, Fridley, Minnesota, 55432, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, 55455, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, 55422, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, 55416, United States|Regions Hospital, Saint Paul, Minnesota, 55101, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States|Saint Joseph's Health Center, Saint Charles, Missouri, 63301, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, 63109, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, 63131, United States|Ozark Health Ventures LLC-Cancer Research for The Ozarks Springfield, Springfield, Missouri, 65804, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, 68122, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Hackensack University Medical CCOP, Hackensack, New Jersey, 07601, United States|Saint Barnabas Medical Center, Livingston, New Jersey, 07039, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|University of New Mexico, Albuquerque, New Mexico, 87106, United States|Albert Einstein College of Medicine, Bronx, New York, 10461, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, 10467-2490, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Winthrop University Hospital, Mineola, New York, 11501, United States|Beth Israel Medical Center, New York, New York, 10003, United States|New York University Langone Medical Center, New York, New York, 10016, United States|Columbia University Medical Center, New York, New York, 10032, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|University of North Carolina, Chapel Hill, North Carolina, 27599, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Southeast Cancer Control Consortium CCOP, Winston-Salem, North Carolina, 27104, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|Roger Maris Cancer Center, Fargo, North Dakota, 58122, United States|Case Western Reserve University, Cleveland, Ohio, 44106, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|Columbus CCOP, Columbus, Ohio, 43215, United States|Dayton CCOP, Dayton, Ohio, 45420, United States|Saint Rita's Medical Center, Lima, Ohio, 45801, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|Sky Lakes Medical Center - Cancer Treatment Center, Klamath Falls, Oregon, 97601, United States|Western Oncology Research Consortium, Portland, Oregon, 97213, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Salem Hospital, Salem, Oregon, 97301, United States|Geisinger Medical Center, Danville, Pennsylvania, 17822, United States|Mercy Fitzgerald Hospital, Darby, Pennsylvania, 19023-1291, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, 19026, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Aria Health-Torresdale Campus, Philadelphia, Pennsylvania, 19114, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, 19141, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Upstate Carolina CCOP, Spartanburg, South Carolina, 29303, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, 38120, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States|Central Vermont Medical Center, Barre, Vermont, 05641, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, 05602, United States|Rutland Regional Medical Center, Rutland, Vermont, 05701, United States|Virginia Oncology Associates-Hampton, Hampton, Virginia, 23666, United States|Virginia Mason CCOP, Seattle, Washington, 98101, United States|Group Health, Seattle, Washington, 98109, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, 99202, United States|Northwest CCOP, Tacoma, Washington, 98405, United States|Saint Vincent Hospital, Green Bay, Wisconsin, 54301, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, 53792, United States|Marshfield Clinic, Marshfield, Wisconsin, 54449, United States|Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Hamilton and District Urology Association McMaster Institute, Hamilton, Ontario, L8N 4A6, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|London Regional Cancer Program, London, Ontario, N6A 4L6, Canada|Ottawa Health Research Institute-General Division, Ottawa, Ontario, K1H 1C4, Canada|Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, H2L 4M1, Canada|McGill University Department of Oncology, Montreal, Quebec, H2W 1S6, Canada|San Juan Veterans Affairs Medical Center, San Juan, 00921-3201, Puerto Rico|San Juan City Hospital, San Juan, 00936, Puerto Rico Less << |
| NCT00154349 | Philadelphia Chromosome Positi... More >>ve Acute Lymphocytic Leukemia Less << | PHASE2 | COMPLETED | 2025-02-07 | - |
| NCT03241199 | Chronic Myeloid Leukemia|Phila... More >>delphia Chromosome Positive CML Less << | PHASE2 | UNKNOWN | 2021-01-01 | The University of Hong Kong, H... More >>ong Kong, Hong Kong Less << |
| NCT02177825 | Plexiform Neurofibromas | PHASE2 | TERMINATED | 2019-03-01 | CHU Sainte-Justine, Montreal, ... More >>Quebec, H3T 1C5, Canada Less << |
| NCT03688568 | Neurofibroma, Plexiform | PHASE2 | WITHDRAWN | 2021-09-01 | Riley Hospital for Children - ... More >>Indiana University, Indianapolis, Indiana, 46202, United States Less << |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.70mL 0.34mL 0.17mL |
8.48mL 1.70mL 0.85mL |
16.96mL 3.39mL 1.70mL |
|
| Dissolving Methods |
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|
|||